Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| University Hospitals Bristol and Weston NHS Foundation Trust | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Ovarian cancer is the eighth most common cause of cancer death in the world. Advanced stage at diagnosis is associated with lower survival rates, thus early detection appears to have an important role.
Raman Spectroscopy is a non-invasive technique that uses the interaction of light to identify the composition of the sample tested.
The aim of the project is to explore the use of spectroscopic techniques in the detection of ovarian cancer. There are two different assessments within the project:
The results of the spectroscopy will be correlated to clinical outcome and histological diagnosis respectively.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Suspected Ovarian Cancer | Patients referred or self presenting to secondary care with signs or symptoms of ovarian cancer. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Ascertain the diagnostic performance of vibrational spectroscopy for detection of Ovarian Cancer | Biomarkers for ovarian cancer will be identified by analysing Raman spectral data of plasma samples taken from patient with ovarian cancer symptoms. Clinical outcome of cancer/no cancer will be used to correlate the results. | 2 years |
| Ascertain the discriminatory ability of vibrational spectroscopy to differentiate between normal, fibrotic and cancerous tissue | Samples taken from post chemotherapy patients will be analysed to identify the spectral signature of ovarian cancer in chemotherapy exposed tissue. | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Performance of vibrational spectroscopy in chemotherapy response prediction | Plasma samples after 1st cycle of chemotherapy will be analysed to evaluate for changes in biomarkers after chemotherapy treatment. | 2 years |
| Performance of vibrational spectroscopy in recurrence prediction |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Patients presenting to secondary care with suspected ovarian cancer symptoms. Patients with likely ovarian cancer, yet to start definitive treatment.
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospitals Bristol and Weston NHS Trust | Bristol | United Kingdom |
Not provided
| ID | Term |
|---|---|
| D010051 | Ovarian Neoplasms |
| D010048 | Ovarian Cysts |
| D010049 | Ovarian Diseases |
| ID | Term |
|---|---|
| D004701 | Endocrine Gland Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D000291 | Adnexal Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Histological sections of tissue specimens of ovary, omentum or peritoneum Blood
Plasma samples after recurrence of cancer will be analysed and compared to initial spectral signature at diagnosis |
| 2 years |
| D005831 |
| Genital Diseases, Female |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D005833 | Genital Neoplasms, Female |
| D014565 | Urogenital Neoplasms |
| D000091662 | Genital Diseases |
| D004700 | Endocrine System Diseases |
| D006058 | Gonadal Disorders |
| D003560 | Cysts |